You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮製藥(01672.HK)漲逾14%重越20天線 於歐洲多國遞交利托那韋上市許可申請
阿思達克 02-14 11:44
歌禮製藥-B(01672.HK)於歐洲多國遞交利托那韋上市許可申請,該股終止三連跌,今早重越10天及20天線(4.3元及4.65元),最高見4.94元,現報4.77元,回升逾14%,成交增至1,219萬股。 歌禮公布,已通過歐洲代理商向德國、法國、愛爾蘭和英國遞交了利托那韋(100毫克薄膜衣片)上市許可申請,其他在歐洲國家、北美國家和亞太國家等的利托那韋上市許可申請也預計將在近期遞交。口服利托那韋片是針對病毒蛋白(酉每)多種口服抗病毒藥物的藥代動力學增強劑及口服抗病毒藥物Paxlovid(奈瑪特韋片+利托那韋片組合包裝)的組成之一。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account